Researchers Evaluated New Neuroblastoma Monitoring Test
A new blood-based profiling method could help clinicians better track disease burden in pediatric patients.
Updated on Oct. 5, 2026 in Cancer
Researchers recently evaluated a cell-free DNA profiling method to monitor neuroblastoma disease burden in pediatric patients with relapsed or refractory cases. This approach, which analyzes 5-hydroxymethylcytosine (5hmC) levels, aims to provide a less invasive way to track the progression of the condition.
Why it matters
Monitoring neuroblastoma often relies on invasive procedures, so developing blood-based methods is a priority for improving long-term care management. This study evaluated how effectively this profiling could mirror clinical disease markers.
This retrospective study utilized 59 plasma samples from 38 pediatric patients to compare a 450-gene neuroblastoma score against a standard TaqMan Low-Density Array assay. The findings indicate how 5hmC profiling correlates with clinical measures like bone marrow tumor involvement.
The players
NANT consortium
A collaborative network of research institutions focused on developing novel therapies and monitoring strategies for neuroblastoma.
The details
The method involves Nano-hmC-Seal sequencing performed on cell-free DNA extracted from patient plasma. By generating whole-genome 5hmC profiles, researchers can analyze gene expression signatures associated with neuroblastoma. This allows clinicians to assess tumor burden by comparing these genomic scores against traditional measures like the Curie score.
Timeline
Samples were collected from participants enrolled in the NANT consortium biology study 2004-05.
Additional participants were enrolled in the NANT 2015-01 study.
Health Landscape
This study advances the field of liquid biopsy research by testing how cell-free DNA can supplement existing cancer monitoring standards. It builds on the existing genomic data framework established by the NANT consortium biology studies.
If you or a family member are managing relapsed neuroblastoma, these findings highlight how emerging blood-based tests are being designed to reduce the frequency of invasive diagnostic procedures. Discuss the availability of diagnostic monitoring trials with your oncologist to understand current options.
The takeaway
Advancements in cell-free DNA profiling offer a promising, less invasive future for monitoring neuroblastoma. Families should keep track of clinical trial updates as these diagnostic methods move toward potential integration into standard oncology care.
Further reading
Learn more about the latest innovations in Cancer care and detection strategies.
More information
View the complete study dataset and documentation for further technical details.
Source note: This article includes information reported by The National Center for Biotechnology Information.
